Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Study is paused - not worried in the slightest

<< Previous

Bullboard Posts

Next >>

Comment by Actuarialon Aug 03, 2021 10:34am

337 Views

Post# 33642031

RE:Study is paused - not worried in the slightest

Today's news is very bad though LTEs doesn't mean liver damage - and still, it is better than if it happens in PIII.

75mg would be the new highest dose for clinical trials.

It is not the end of the world as OtenA has the potential to go lower.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China